Galectin Therapeutics Inc. (GALT)

[SunshineSmiles]

GALT

Clinical Trials:

Phase 1: https://clinicaltrials.gov/ct2/show/NCT02575404?term=GR-MD-02&rank=1

Phase 1 open label: https://clinicaltrials.gov/ct2/show/NCT02117362?term=GR-MD-02&rank=6

Phase 2: We hope to report additional data in early 2018 when we anticipate a decision on progressing to Phase 2. This decision will be based on the response rate of the combination of pembrolizumab with GR-MD-02 as compared to historical response rates to pembrolizumab alone,” he said.

https://immuno-oncologynews.com/2017/02/15/combination-immunotherapy-galectin-3-inhibitor-gr-md-02-enhances-effects-in-pre-clinical-models-and-early-results-of-phase-1-clinical-trials/